JPMorgan, Goldman Sachs, Citibank, BofA, PNC and Wells Fargo arranged both facilities. The term loan funds only if the Xodus Medical purchase closes, and its leverage covenant loosens for four quarters after a large acquisition.
The Philadelphia skyline across the Delaware River. Photo: Haimbd, CC0, via Wikimedia Commons.
The refinancing ends a paid-in-kind loan and its payoff multiple, but the new interest is due in cash, the maturity moves out less than three months, and the covenants now allow far more convertible debt.
The $500,000 upfront value is mostly a 9.4% stake in REA Holdings, a buyer led by the former chairman of NewcelX's predecessor. Up to $55 million in milestones and 2% to 8% royalties depend on future development.
Evommune will pay Hinova $20 million in cash plus pre-funded warrants for 1,262,413 shares, and sold 4,966,889 shares at $6.04 through Morgan Stanley and Leerink. EVO756 missed its endpoints in hives and eczema this year.
The equity plan starts at 18% of the combined company and can add 5% of fully diluted shares each year to 2036. Rallybio holders take a $13.90 a share cash payout and keep about 2.8%.
The variable-price note can convert as low as US$0.1449 a share, and the warrant alone is about 2.4 times the shares outstanding in October. The going concern company can ask the same lender for more notes every quarter from January.
Nasdaq gave the former Cyclacel until April 27, 2027 to get back above $1.00. The company points to a reverse split tied to a $2 billion share deal with a Malaysian waste firm, which goes to a vote on November 19.
The unsecured bridge note pays 9% and has no covenants or equity feature. Univest Securities has collected placement fees on four raises since October 2025 and holds first-refusal rights on future deals and a sale.
The notes mature June 30, 2027 and convert at 85% of recent prices down to a $0.20 floor. ABVC had $31,944 in cash at June 30 and reports substantial doubt about its ability to continue as a going concern.
Lenders and noteholders would own 55% of the combined company and receive myelofibrosis sales rights. Shareholders get nothing, and Karyopharm expects its stock to be delisted.
Most of what the note paid out went to retire $71,557 of older convertible debt. The equity line sells stock at 80% of the lowest recent price and cannot start until an S-1 is effective.
ProKidney can sell up to $200,000,000 of Class A stock through Jefferies LLC at a commission of up to 3.0%, under a $650,000,000 shelf that the filings say must take effect before any sale. The stock last sold at $1.52 on October 28, 2026.
Lexeo's new Form S-3 would let it sell up to $300,000,000 of securities and rolls over $135,387,220.20 of unsold securities from a December 2024 shelf. No offering has been priced.
The offering priced at $1.50 a share, and the warrants carry a $1.65 exercise price. The auditor's report on the 2025 accounts includes a going-concern paragraph, and cash was $18.4 million at June 30, 2026.
FOXO Technologies signed agreements to acquire preferred stock carrying majority voting power in Ludwig Enterprises, Inc. and to buy certain Ludwig notes. The transactions have not closed.
Altimmune drew $10.0 million on October 27, 2026, and the draw extended the interest-only period to June 1, 2028 while adding a minimum cash covenant tied to the loan balance.
Public drug developers and pharmaceutical makers in our directory, across 58 countries and territories. The US has the most. China, India and South Korea together have more.
Source: aibio.space company directory, research date October 22, 2026. One row per issuer.
Companies by country
United States680
China417
India219
South Korea206
Taiwan140
Japan93
Canada92
Sweden74
Free membership
Read the companies you follow. Subscribe free for email updates.
Each desk collects the company's filings, press releases and outside coverage, and adds our view of the science, the odds and the balance sheet.
Free membership
Read freely. Subscribe for email updates.
Read every story, desk and company profile for free. Subscribe if you would like updates and offers by email. Unsubscribe in one click.